Detailansicht

Wissensnetz

Person

Hans-Georg Rammensee (1953-)

Biologe

Name	Hans-Georg Rammensee
Zeit	1953- (Lebensdaten)
Ort	Tübingen (Geburtsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr.
Beruf	Biologe (charakteristischer Beruf) Hochschullehrer
Themengebiet	Personen zu Medizin, Tiermedizin
Weitere Angaben	Dt. Biologe; Leibniz-Preis 1992, Immunologie, MPI für Biologie, Tübingen; Prof. in Tübingen
Quelle	LCAuth Internet Landesbibliographie Baden-Württemberg
Datensatztyp	Person
GND-Nummer	118032127
Datensatz-ID	118032127
Beteiligt an alle anzeigen A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2 HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency A T-cell antigen atlas for meningioma: novel options for immunotherapy DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function Designing a SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups Use of novel insertion sites for the development of polyvalent ORFV D1701-V vectored vaccines Individualisierte Immuntherapie von Tumorerkrankungen mittels Peptidimpfstoffen – Funktioniert das vielleicht doch? SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma Actively personalized vaccination trial for newly diagnosed glioblastoma First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications Personalized cancer vaccines: adjuvants are important, too The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes SYFPEITHI: database for MHC ligands and peptide motifs MHC ligands and peptide motifs MHC Ligands and Peptide Motifs MHC molecules and peptides : structure and functions Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules Identification of classical minor histocompatibility antigen as cell-derived peptide Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine Evidence from in vitro studies that tolerance to self antigens is MHC-restricted Regulation und Effektorphase der Immunantwort gegen schwache Histokompatibilitätsantigene

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Hans-Georg Rammensee (1953-)

A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

A T-cell antigen atlas for meningioma: novel options for immunotherapy

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens

SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function

Designing a SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups

Use of novel insertion sites for the development of polyvalent ORFV D1701-V vectored vaccines

Individualisierte Immuntherapie von Tumorerkrankungen mittels Peptidimpfstoffen – Funktioniert das vielleicht doch?

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Actively personalized vaccination trial for newly diagnosed glioblastoma

First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications

Personalized cancer vaccines: adjuvants are important, too

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy

Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies

Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes

SYFPEITHI: database for MHC ligands and peptide motifs

MHC ligands and peptide motifs

MHC Ligands and Peptide Motifs

MHC molecules and peptides : structure and functions

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

Identification of classical minor histocompatibility antigen as cell-derived peptide

Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells

Clonal anergy induced in mature V beta 6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

Evidence from in vitro studies that tolerance to self antigens is MHC-restricted

Regulation und Effektorphase der Immunantwort gegen schwache Histokompatibilitätsantigene